- Home
- PLRX vs FATE Comparison
PLRX vs FATE Comparison
Compare PLRX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- FATE
- Stock Information
- Founded
- PLRX 2015
- FATE 2007
- Country
- PLRX United States
- FATE United States
- Employees
- PLRX N/A
- FATE N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLRX Health Care
- FATE Health Care
- Exchange
- PLRX Nasdaq
- FATE Nasdaq
- Market Cap
- PLRX 90.9M
- FATE 152.4M
- IPO Year
- PLRX 2020
- FATE 2013
- Fundamental
- Price
- PLRX $1.45
- FATE $1.10
- Analyst Decision
- PLRX Hold
- FATE Hold
- Analyst Count
- PLRX 10
- FATE 8
- Target Price
- PLRX $9.79
- FATE $5.43
- AVG Volume (30 Days)
- PLRX 744.6K
- FATE 2.1M
- Earning Date
- PLRX 05-20-2025
- FATE 05-12-2025
- Dividend Yield
- PLRX N/A
- FATE N/A
- EPS Growth
- PLRX N/A
- FATE N/A
- EPS
- PLRX N/A
- FATE N/A
- Revenue
- PLRX N/A
- FATE $13,631,000.00
- Revenue This Year
- PLRX N/A
- FATE N/A
- Revenue Next Year
- PLRX N/A
- FATE N/A
- P/E Ratio
- PLRX N/A
- FATE N/A
- Revenue Growth
- PLRX N/A
- FATE N/A
- 52 Week Low
- PLRX $1.10
- FATE $0.66
- 52 Week High
- PLRX $16.52
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- PLRX 41.87
- FATE 49.64
- Support Level
- PLRX $1.36
- FATE $0.91
- Resistance Level
- PLRX $1.72
- FATE $1.34
- Average True Range (ATR)
- PLRX 0.11
- FATE 0.13
- MACD
- PLRX 0.04
- FATE -0.03
- Stochastic Oscillator
- PLRX 29.17
- FATE 32.76
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.